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Abstract
Introduction: Androgen deprivation therapy (ADT) has detrimental effects on body composition, metabolic health,
physical functioning, bone mineral density (BMD) and health-related quality of life (HRQOL) in men with prostate
cancer. We investigated whether a 12-month home-based progressive resistance training (PRT) programme,
instituted at the start of ADT, could prevent these adverse effects.
Methods: Twenty-five patients scheduled to receive at least 12 months of ADT were randomly assigned to either
usual care (UC) (n = 12) or PRT (n = 13) starting immediately after their first ADT injection. Body composition, body
cell mass (BCM; a functional component of lean body mass), BMD, physical function, insulin sensitivity and HRQOL
were measured at 6 weeks and 6 and 12 months. Data were analysed by a linear mixed model.
Results: ADT had a negative impact on body composition, BMD, physical function, glucose metabolism and
HRQOL. At 12 months, the PRT group had greater reductions in BCM by − 1.9 ± 0.8 % (p = 0.02) and higher gains in
fat mass by 3.1 ± 1.0 % (p = 0.002), compared to the UC group. HRQOL domains were maintained or improved in
the PRT versus UC group at 6 weeks (general health, p = 0.04), 6 months (vitality, p = 0.02; social functioning, p =
0.03) and 12 months (mental health, p = 0.01; vitality, p = 0.02). A significant increase in the Matsuda Index in the
PRT versus UC group was noted at 6 weeks (p = 0.009) but this difference was not maintained at subsequent
timepoints. Between-group differences favouring the PRT group were also noted for physical activity levels (step
count) (p = 0.02). No differences in measures of BMD or physical function were detected at any time point.
Conclusion: A home-based PRT programme instituted at the start of ADT may counteract detrimental changes in
body composition, improve physical activity and mental health over 12 months.
Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12616001311448
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Key points
 Androgen deprivation therapy (ADT) used in the
treatment of prostate cancer has negative effects on
body composition, muscle strength, insulin
sensitivity and health-related quality of life
(HRQOL)
 A 12-month home-based progressive resistance
training (PRT) programme can offset detrimental
changes in body composition, physical activity and
HRQOL when initiated at the start of ADT
 A home-based PRT programme can potentially offer
clinicians a viable alternative to more resource-
intensive supervised programmes
Introduction
Prostate cancer has the second highest incidence of all
cancers amongst men worldwide and is the fifth leading
cause of cancer death in men [1]. Androgen receptor
signalling strongly promotes prostate cancer growth.
Thus, androgen deprivation therapy (ADT) with gonado-
trophin releasing hormone (GnRH) analogues is a com-
monly utilised therapy for men with prostate cancer.
However, in rendering patients severely hypogonadal,
ADT is associated with multiple adverse effects. Changes
in body composition occur rapidly, with increases of 7–
10% in fat mass (FM), and decreases of 2–4% in lean
body mass (LBM) after 1 year of ADT [2], with these
effects persisting up to two years following cessation [3].
Patients also experience a reduction in muscle strength
and bone mineral density (BMD), increased risk of type
2 diabetes and deterioration of health-related quality of
life (HRQOL) [4].
Physical exercise is currently recognised as an effective
strategy to ameliorate many of the adverse effects of
ADT [5]. Clinical trials have shown both resistance and
aerobic exercise improve body composition, metabolic
profile, functional capacity, fatigue and HRQOL [5].
Progressive resistance training (PRT) is defined as an
exercise modality that involves challenging the skeletal
muscles with unaccustomed loads to improve muscle
mass and fitness (i.e. muscle endurance, strength and
power and range of motion) over time [6]. It is well
established that PRT is beneficial in the treatment of
sarcopenia in older men and women [7] and is also effi-
cacious in the treatment of ADT-induced adverse effects
particularly in regards to muscle strength and body com-
position [8].
There are limitations relating to exercise intervention
studies in prostate cancer. Firstly, much of the evidence
has been derived from studies enrolling patients on
stable ADT after an average treatment time of 14
months [9], while it has been shown that the develop-
ment of adverse effects is the most pronounced during
the initial months of ADT [10, 11]. To date, two studies
have examined the benefits of a supervised exercise
programme in the prevention of adverse effects when
administered at the initiation of ADT. Cormie et al. [9]
showed a preservation of appendicular LBM and preven-
tion of gains in whole body FM, when compared to
usual care. Using a similar intervention, Taaffe et al. [12]
showed preservation of LBM and BMD after 6 months
in an immediate versus delayed (waitlist) exercise groups.
However, these differences became non-significant after
the waitlist group completed 6months of training (i.e. at
12months). Secondly, studies to date have implemented
supervised training programmes in exercise clinics. While
compliance rates are superior compared to home-based
exercise [13, 14], fully supervised programmes are re-
source intensive, less accessible and transitioning to
community-based programmes after a period of close
supervision can be confronting for some patients [15, 16].
Thus, more evidence is needed regarding the feasibility
and efficacy of home-based exercise programmes. The in-
clusion of home-based exercise prescriptions is likely
needed for the successful implementation of exercise re-
habilitation as standard practice in cancer care, as recom-
mended by the Clinical Oncological Society of Australia
and exercise clinicians [17, 18].
We hypothesise that the introduction of a 12-month
home-based PRT programme at the start of ADT can
prevent detrimental changes in body composition, phys-
ical function, metabolic derangements and HRQOL. The
primary aim of this study was to investigate the effect of
PRT on body composition. As a secondary analysis, we
examined the effect of PRT on physical function, BMD
and HRQOL at 12months
Methods
This was a 12-month randomised controlled study of
(PRT) in patients with prostate cancer commencing
ADT. Over a period of 24 months, men with prostate
cancer scheduled to receive conventional ADT with
GnRH analogues were invited by their treating oncolo-
gist to participate in this study. Recruitment took place
at the Crown Princess Mary Cancer Centre, Westmead
Hospital and the Blacktown Cancer and Haematology
Centre, Blacktown Hospital, Australia. Inclusion criteria
were men aged between 50 and 80 years with histologi-
cally confirmed prostate cancer of early or locally ad-
vanced stage with ≤ 5 sites of metastases and Eastern
Cooperative Oncology Group (ECOG) 0 performance
status. Exclusion criteria included concurrent chemo-
therapy or anti-androgen therapy, previous ADT within
the last 12 months, or any musculoskeletal, cardiovascu-
lar and/or neurological disorders that could inhibit them
from exercising. This study was approved by the Western
Sydney Local Health District Human Research Ethics
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Committee. The study was conducted in accordance with
the principles of the Declaration of Helsinki. All partici-
pants gave written consent. The study was registered with
the Australian and New Zealand Clinical Trials Registry
(ACTRN12616001311448, date of registration 19th
September 2016, retrospectively registered). A total of 40
patients were screened and 25 patients randomised into
the study (Fig. 1).
Experimental design
A two-armed prospective randomised controlled trial
design was implemented. The 25 men were randomised
into two arms: PRT (13 men) or usual care (UC) (12
men) using a computer random assignment programme.
As part of routine care, all participants received non-
standardised advice from the treating clinician to partici-
pate in regular exercise throughout the intervention
period.
PRT intervention
Participants assigned to the PRT group undertook 52
weeks of a home-based PRT programme starting soon
after their first ADT injection. The resistance training
regimen was designed to stimulate all major skeletal
muscle groups and exert beneficial effects on all out-
comes. The programme was designed and progressed
according to standard training principles and adapted to
the needs of the cohort and individual participants en-
rolled in the study. Resistance training was performed
three times per week, with 8–10 exercises targeting the
major muscle groups using adjustable dumbbells or body
weight loading (callisthenics). Patients performed three
sets per exercise using 8–12 repetitions maximum (RM)
loading. The difficulty and/or the loading of each exer-
cise was advanced on an individualised basis, with
strength adaptation, i.e. once the participant was capable
of performing greater than 12 repetitions per set [19].
There were three stages of exercises outlined in Table 1.
Patients advanced to the next stage after 12 weeks, de-
pending on their confidence in consultation with the
supervising exercise physiologist.
One week of exercise supervision (two sessions) were
provided at baseline to instruct patients in proper lifting
techniques and loading progressions. Patients then
returned for a supervised session every 12 weeks to learn
the next stage of exercises and to ensure proper tech-
niques were being utilised at home. To maximise adher-
ence, online instructional videos and a printed training
manual was provided for each exercise, and patients
were given monthly reminder phone calls. Adherence to
exercise was recorded in a training logbook by patients.
Overall activity levels of all participants were monitored
Fig. 1 Consort diagram
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by physical activity questionnaires and total step counts
for 1 week (via a pedometer) prior to their study visits.
Endpoints
Study endpoints were assessed at baseline, 6 weeks, 6
months, and 12 months of ADT.
Body composition and bone mineral density
The primary endpoint was a change in LBM. LBM and
total and regional FM were assessed by dual x-ray ab-
sorptiometry (DXA; GE Healthcare Lunar Prodigy Pro)
and bioeletrical impedance spectroscopy (BIS) using the
ImpediMed Ltd SFB7 analyser (ImpediMed Ltd Qld,
Australia) [20]. Change in body cell mass (BCM), a func-
tional component of LBM, was estimated by subtracting
extracellular water (ECW) from LBM. Vertebral and hip
bone mineral density was also measured by DXA at each
visit.
Physical activity
A pedometer (G-Sensor 2026) was used to estimate step
counts for 1 week prior to each visit. Patients were asked
to complete an exercise diary for 1 week prior to each
visit and to specify the number of hours of light, moder-
ate or intense physical activity. Patients in the PRT
group were instructed not to include the intervention in
their documented activity, but to only include other
types of physical activity.
Physical function
A series of standard tests were used to assess physical
function. Maximal strength of the upper and lower body
was assessed by an isometric dynamometer (i.e. triceps
extension and knee extension) (Chatillon CSD200, JLW
Instruments, Chicago, USA) hand grip strength by a
dynamometer (Jamar Plus digital dynamometer). The
best performance over 3 trials was recorded. Function
lower extremity strength was assessed using the sit-to-
stand test [21]. The participant is encouraged to complete
as many full stands from a chair as possible within 30 s.
The timed get-up-and-go test (TUGT) was used to evalu-
ate dynamic balance and physical performance [22]. From
a seated position, the participants stood, walked 3m,
turned around, walked back to the chair, returning to a
seated position as quickly as possible (best performance
out of three recorded). The Lord sway-meter was used to
assess co-ordinated stability, which measures participants’
ability to adjust balance in a steady and co-ordinated way
while placing them near or at the limits of their base of
support. This test uses a 40-cm rod attached to the par-
ticipant at waist level by a firm belt. Participants are then
asked to adjust balance by bending or rotating their body
without moving their feet, so that a pen mounted verti-
cally at the end of the rod remains within a convoluted
track. A total error score is calculated [23]. The postural
sway test was used to assess dynamic balance. Participants
stood barefoot on the floor or foam surface with open and
closed eyes. The test records sway path, maximal anterior-
posterior and lateral sway, measured by the Physiological
Profile Assessment (PPA) Sway Path Mobile Applications
(NeuRa) on an iPad attached to the top of an adjustable
height table [24]. Aerobic capacity (submaximal VO2) was
measured by a cycle ergometer (Lode Corival Recumbent
Ergometer) and data analysed using LEM software.
Glucose and insulin indices
Glucose metabolism was assessed using the oral glucose
tolerance test (OGTT). Blood glucose and insulin con-
centrations were measured at baseline and after a 75-g
glucose load at 30, 60, 90, and 120 min. Hepatic insulin
resistance (the product of total area under the curve for
glucose and insulin during the first 30 min) and muscle
insulin sensitivity (the rate of decay of plasma glucose
concentration from its peak value to its nadir divided by
the mean insulin concentration) were calculated [25].
Using the OGTT results, calculations were made of the
HOMA-IR, the oral disposition index [26], Matsuda
index (index of insulin sensitivity) [27] and overall glucose
metabolism was estimated as the incremental glucose area
under the curve above fasting over 120min [26].
Quality of life
HRQOL was assessed at each study visit by the Short
Form 36 version 2.0 (SF-36v2) physical and psycho-
logical health survey.
Statistical analysis
Sample size calculation was based on change in body
composition as indicated by LBM. Previous research in-
volving PRT in men receiving ADT indicated a differ-
ence in LBM of 0.8 ± 0.4 kg between groups after a 12
week PRT intervention [28, 29]. Nine participants in
each group were required to achieve 80% power at an α
level of 0.05. Based on past studies involving supervised
Table 1 Exercise stages
Stage 1 Stage 2 Stage 3
Incline push-up Incline push-up Standard push-up
Bent over row Bent over row Decline push-up
Biceps curl Biceps curl Curl to press
Triceps extension Triceps extension Chair dips
Side shoulder raise Side shoulder raise Lunge
Dumbbell squat Dumbbell squat Side shoulder raise
Split squat Split squat Dumbbell squat
Straight leg deadlift Straight leg deadlift Straight leg deadlift
Shoulder press
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exercise programmes, an attrition rate of at least 20 % is
expected. Therefore, to ensure we had sufficient partici-
pant numbers at the end of the intervention, 25 partici-
pants were randomised to the study arms (UC group 12
men; PRT group 13 men).
The statistical analysis consisted of a linear mixed ef-
fects model, using a random patient effect to account for
differences in baseline and fixed effects for the visit and
intervention arm. In this analysis, a difference in time
course behaviour between study arms corresponded to
an interaction between visit and intervention. Compari-
sons at specific time points were made using contrasts
extracted from the mixed effects model and separately
using two-sample t tests of change in endpoint. Results
are expressed as mean ± S.E.M and unadjusted P values
were utilised. A P value < 0.05 was considered signifi-
cant. All analysis was conducted in R version 3.6.0
(Vienna, Australia), RStudio IDE (Boston, MA) and SPSS
statistics v22 (IBM corporation).
Results
Baseline patient characteristics and retention
At baseline, 12 were enrolled in the UC arm and 13 par-
ticipants in the PRT arm. At 6 months, one participant
in the UC arm was unable to attend follow-up due to
hospitalisation (but remained in the study) and one par-
ticipant in the PRT arm discontinued the study. At 12
months, two participants discontinued the study (one
from each arm) and two patients from each arm were
excluded from final analysis as ADT was discontinued
for more than 3months prior to their 12-month visit
(one from each arm). Thus, at 12 months, 10 partici-
pants remained in each arm (Fig. 1).
At 12 months, 50% of patients had progressed onto
stage 3 exercises, 30% remained at stage 2 and 20%
remained at stage 1. Patients did not progress to the
next stage of exercises if they lacked the confidence and/
or the ability to do so. Out of the 13 participants, one
consistently did not comply with filling in his logbook
citing poor literacy as the reason, although he reported
full compliance with the PRT programme. Logbook ana-
lysis showed that from baseline to 6 weeks, all partici-
pants completed 100% of the exercise sessions (3
sessions/week); from 6 weeks to 6 months, an average of
2.3 sessions/week were completed; and from 6 to 12
months, an average of 2.2 sessions/week were completed.
At baseline (Table 2), UC and PRT participants were
well matched in terms of age, blood pressure, number of
co-morbidities and medications, body composition and
PSA levels, as well as prostate cancer grade and stage.
Pre-treatment testosterone levels were significant higher
in the UC group (p = 0.02), but both groups had similar
suppressed testosterone levels during ADT. There were
no significant differences between groups in terms of
baseline activity level as assessed by pedometer step
counts and hours of light, moderate or intense physical
activity.
Response to ADT
Following administration of ADT in the whole cohort
serum testosterone levels significantly decreased from 14.2
± 0.8 nmol/L at baseline to 0.2 ± 0.03 nmol/L (p < 0.0001)
at 12months. Similarly, serum PSA levels fell from 9.7 ±
1.4 ng/mL to 0.4 ± 0.2 ng/mL (p < 0.0001) at 12months.
To eliminate possible PRT effect on ADT-induced ef-
fect size, the ADT effect is reported only in the UC
group, described in detail in Supplementary Table 1. At
12 months, there was a significant reduction in BCM
(BCM %) and increase in FM (FM %) as a percentage of
total body mass (TBM) by 4.6 ± 0.6 % and 5.5 ± 0.6 %
(p < 0.001), respectively (Table 3). Similarly, there were
Table 2 Baseline clinical characteristics
Variable UC (n = 12) PRT (n = 13) p value
Age (years) 71.8 ± 1.8 69.3 ± 2.3 0.14
Weight (kg) 79.9 ± 2.7 87.2 ± 4.7 0.03
BMI kg/m2 28.8 ± 1.1 29.7 ± 1.3 0.36
Number of co-morbiditiesa 0.9 ± 0.2 1.5 ± 0.2 0.81
Number of medications 1.1 ± 0.3 1.5 ± 1.1 0.91
SBP (mmHg) 137 ± 2 139 ± 4 0.18
DBP (mmHg) 74 ± 3 74 ± 1 0.11
Gleason score 7.6 ± 0.3 8.2 ± 0.2 0.42
Cancer staging
Localised (n) 9 8 0.36
Biochemical recurrence (n) 3 3
Metastatic (n) 0 2
Previous radiotherapy (n) 8 5 0.39
Previous ADT (n) 0 2 0.26
Lean body mass (kg) 53.1 ± 1.2 54.5 ± 2.2 0.16
LBM (% body weight) 66.5 ± 1.8 63.2 ± 2.0 0.68
Fat mass (kg) 24.2 ± 2.1 29.9 ± 3.2 0.12
Extracellular water (L) 19.0 ± 0.6 19.8 ± 0.9 0.05
BCM (kg) 34.1 ± 1.0 34.7 ± 1.3 0.58
Testosterone (nmol/L) 16.1 ± 1.1 12.5 ± 0.8 0.02
LH (mIU/mL) 7.0 ± 0.7 6.3 ± 0.7 0.70
PSA (ng/mL) 10.3 ± 3.3 7.7 ± 1.3 0.08
Step count (number) 40172 ± 8502 28838 ± 5377 0.14
Light physical activity (h) 5.9 ± 1.6 7.9 ± 2.5 0.09
Moderate physical activity (h) 3.9 ± 1.8 3.3 ± 1.4 0.93
High physical activity (h) 0.1 ± 0.1 0.5 ± 0.3 0.05
Data are presented as mean ± S.E.M
p value is for UC vs PRT group; BMI body mass index, LBM lean body mass,
BCM body cell mass, LH luteinizing hormone, PSA prostate-specific antigen
aCardiovascular disease, respiratory disease, arthritis, hypertension,
dyslipidemia, diabetes, osteoporosis
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significant increases in fasting glucose by 0.7 ± 0.1
mmol/L (p < 0.001) and hepatic insulin resistance by
31.9 ± 11.3 (p < 0.01). There was a significant reduction
in insulin sensitivity as represented by the Matsuda
Index by 1.8 ± 0.5 (p < 0.01). BMD also significantly de-
creased at the lumbar spine by 0.01 ± 0.02 (p < 0.01) as
did muscle strength, with a reduction in right hand grip
by 4.2 ± 1.0 N (p < 0.001), left hand grip by 3.4 ± 1.1 N
(p < 0.01) and lower limb strength by 50.9 ± 20.4 N (p <
0.05). There was a reduction in physical function as
reflected by a prolongation in the TUGT by 0.3 ± 0.2 s
(p = 0.04). HRQOL as measured by the SF36v2 mental
component summary (MCS) score also decreased but
did not reach significance at 12 months (p = 0.08).
Effect of PRT
Body composition
The effect of PRT on changes in body composition is
shown in Fig. 2 and described in detail in Supplementary
Table 2. At 6 weeks and 6months, there was a trend to-
wards a greater reduction in LBM % and BCM % in the
UC versus PRT group but this did not reach statistical
significance. At 12 months, the PRT group significantly
maintained LBM by 2.7 ± 0.8 % (p = 0.001) and BCM by
1.9 ± 0.8 % (p = 0.02) (Fig. 2a) versus the UC group.
Similarly, patients in the PRT group experienced less of
a gain in fat mass, with a − 3.1 ± 1.0 % (p = 0.002) differ-
ence between the two groups at 12 months (Fig. 2b).
When assessing regional fat mass, the largest difference
was observed in truncal fat mass (p = 0.02), with the
PRT group gaining 1.8 ± 0.8 kg less than the UC group
at 12 months (Table 4).
Physical function and BMD
A detail description of the changes in physical function
and BMD is provided in Supplementary Table 3. There
were no differences in BMD, muscle strength, physical
function (balance and co-ordinated stability) or submaxi-
mal VO2 between the UC and PRT groups. However,
there was a significant increase in physical activity levels
as measured by step count in the PRT compared to the
UC group at 12 months (p = 0.02) (Table 4).
Glucose and insulin indices
At 6 weeks, there was a decrease in the Matsuda Index
in the UC group by − 0.3 ± 0.5 (p = 0.47) and a signifi-
cant increase in the PRT group by 2.2 ± 0.7 (p = 0.009)
with an overall difference between groups of 2.5 ± 0.8
(p = 0.004) (Table 4; Supplementary Table 4). However,
this significant early difference was not maintained at 6
and 12months. There were no significant differences be-
tween groups in terms of plasma insulin and glucose
Table 3 Effect of ADT on body composition, metabolism and physical function in the UC group at 12 months
Baseline (n = 10) 12months (n = 10) p value
Total mass (kg) 80.1 (3.0) 82.0 (3.0) 0.002
BCM (%) 43.6 (2.0) 39.0 (1.4) < 0.001
FM (%) 29.4 (2.1) 34.9 (1.5) < 0.001
Neck of femur BMD (left total) 1.011 (0.04) 1.001 (0.04) 0.28
Neck of femur BMD (right total) 1.01 (0.05) 0.99 (0.04) 0.13
Lumbar spine BMD 1.42 (0.06) 1.36 (0.07) 0.005
Fasting glucose (mmol/L) 4.7 (0.2) 5.4 (0.2) < 0.001
Fasting insulin (IU/L) 7.1 (2.2) 11.7 (2.3) 0.22
Matsuda index 6.5 (1.0) 4.7 (0.8) 0.002
HOMA-IR 1.6 (0.5) 2.9 (0.7) 0.11
Hepatic insulin resistance 43.7 (12.5) 74.0 (22.7) 0.008
Muscle insulin resistance 1.0 (0.4) 1.3 (0.6) 0.38
Co-ordinated stability (corners) 0.5 (0.5) 0.8 (0.3) 0.05
Right hand grip (N) 37.5 (1.8) 33.2 (1.7) < 0.001
Left hand grip (N) 34.0 (1.5) 30.9 (1.6) 0.004
Upper limb strength (N) 150.8 (14.1) 145.8 (11.3) 0.35
Lower limb strength (N) 297.2 (26.7) 239.5 (15.6) 0.02
Sit-to-stand test (number) 17.0 (1.3) 18 (1.5) 0.17
TUGT (s) 5.8 (0.3) 6.0 (0.3) 0.04
SF36v2 MCS score 58.4 (1.3) 55.4 (2.1) 0.08
Data are presented as mean ± S.E.M; p value represents change compared to baseline in the UC group at 12 months; BCM body cell mass, FM fat mass, BMD bone
mineral density, TUGT timed get-up-and-go test, IGF-1 insulin-like growth factor, IGFBP-3 insulin-like growth factor binding protein 3
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Table 4 Group differences in the endpoints of body composition, physical activity, glucose and insulin indices and HRQOL at 6
weeks, 6 months and 12 months, reflecting the effect of PRT
Variables 6 weeks p value 6months p value 12months p value
Body composition
Total mass (kg) 1.5 (0.9) 0.09 0.5 (0.9) 0.60 − 1.0 (0.9) 0.30
Total LBM (% total mass) 0.5 (0.8) 0.47 1.3 (0.8) 0.11 2.7 (0.8) 0.001
Total BCM (% total mass) 1.0 (0.8) 0.21 1.3 (0.8) 0.10 1.9 (0.8) 0.02
Total FM (% total mass) − 0.4 (0.9) 0.65 − 1.1 (0.9) 0.25 − 3.1 (1.0) 0.002
FM trunk (kg) − 0.1 (0.7) 0.94 − 0.8 (0.7) 0.39 − 1.8 (0.8) 0.02
Physical activity
Step count 12864 (7102) 0.08 7719 (7308) 0.30 19188 (7805) 0.02
SF36v2 health survey
Physical functioning 0.3 (2.6) 0.89 − 2.1 (2.7) 0.45 1.3 (2.8) 0.63
Role—physical 0.002 (2.1) 0.99 1.5 (2.2) 0.51 − 0.6 (2.3) 0.81
Bodily pain 5.0 (2.3) 0.03 0.3 (2.4) 0.91 2.6 (2.5) 0.30
General health 5.0 (2.4) 0.04 1.0 (2.6) 0.69 2.7 (2.6) 0.32
Vitality 3.8 (2.4) 0.11 5.8 (2.5) 0.02 6.0 (2.5) 0.02
Social functioning 2.7 (1.9) 0.15 4.2 (1.9) 0.03 2.1 (2.0) 0.31
Role—emotional 1.8 (2.2) 0.43 2.6 (2.3) 0.28 1.9 (2.4) 0.43
Mental health 2.8 (2.2) 0.21 3.7 (2.3) 0.12 4.9 (2.4) 0.04
Physical component summary 1.6 (1.8) 0.40 − 1.7 (1.9) 0.37 − 0.1 (2.0) 0.97
Mental component summary 3.4 (1.9) 0.08 5.7 (2.0) 0.006 5.5 (2.1) 0.01
Glucose/insulin indices
Glucose (mmol/L) fasting − 0.1 (0.2) 0.73 0.2 (0.2) 0.34 0.01 (0.2) 0.94
Insulin (IU/L) fasting − 5.2 (3.8) 0.18 − 1.6 (3.9) 0.68 3.2 (4.1) 0.44
Matsuda Index 2.5 (0.8) 0.004 0.4 (0.8) 0.64 − 0.04 (0.9) 0.96
Data are presented as mean ± S.E.M; p value represents mean differences between the UC and PRT groups at 6 weeks, 6 months and 12months; BCM body cell
mass, FM fat mass
Fig. 2 The effect of PRT on body composition. a Change in body cell mass (% total body mass) in the UC and PRT groups at 6 weeks and 6 and
12months (**p = 0.01 reflects difference between the groups at 12 months). b Change in fat mass (% total body mass) in the UC and PRT groups
at 6 weeks and 6 and 12 months (**p = 0.02 reflects difference between the groups at 12 months)
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levels, HOMA-IR, disposition index, or liver and muscle
insulin resistance.
Quality of life
The effect of PRT on HRQOL is summarised in Table 4
and described in detail in Supplementary Table 5. At 6
weeks, there was a reduction in the SF36v2 general
health score in the UC group and an increase in the
PRT group, with a significant difference of 5.0 ± 2.4 (p =
0.04) between the two groups. At 6 months, there were
significantly greater reductions in the SF36v2 scores for
vitality (p = 0.02) and social functioning (p = 0.03) in the
UC compared to the PRT group. At 12 months, the
SF36v2 scores for vitality and mental health both im-
proved in the PRT group, as opposed to a reduction in
the UC group (Fig. 3a, b).
Intervention safety and adherence
In terms of adverse events, one patient in the PRT group
developed right shoulder pain (rotator cuff tendonitis) at
the completion of the study, requiring physiotherapy.
Discussion
This randomised controlled trial examined the efficacy
of a 12-month home-based PRT programme in the
prevention of the adverse effects of ADT. Our study
demonstrated the detrimental effects of ADT on body
composition, insulin resistance, BMD, physical function
and HRQOL. We showed that the early implementation
of a 12-month home-based PRT programme at the start
of ADT resulted in beneficial effects on body composition
and physical activity levels, and improvements in HRQOL.
After 12 months of ADT, we found a significant reduc-
tion in BCM (a functional component of LBM) and a
significant increase in FM in the UC group. This was ac-
companied by a significant increase in insulin resistance
and reduction in insulin sensitivity, as measured by the
HOMA-IR and Matsuda index, respectively, at 6 and 12
months. As expected, there were reductions in BMD,
muscle strength and physical function following 12
months of ADT.
This study showed that a home-based PRT programme
was able to significantly counteract ADT-induced changes
in body composition. PRT was able to offset reductions in
LBM by 1.2 ± 0.2 kg at 12months. Importantly, a similar
effect of PRT was also seen with BCM, a functional com-
ponent of LBM which has not been examined previously.
Using a supervised PRT programme, Nilsen et al. [30]
found a preservation of LBM in the PRT group, while a
12-month study conducted by Winters-Stone et al. [31]
did not show any differences in LBM between the PRT
and control group. However, participants in this study by
Winters-Stone et al. were undergoing ADT two to three
times longer than that of Nilsen et al., indicating that the
benefit of exercise on LBM may diminish with longer dur-
ation of ADT [31]. Despite a lower intensity home-based
programme, we were able to demonstrate a significant
effect of PRT on LBM and BCM. This highlights the
powerful effect of PRT on muscle, and the need for early
implementation of PRT before detrimental changes in
body composition occur.
Fig. 3 Improvements across SF-36v2 domains after 12 months of PRT. a Change in the SF-36v2 vitality score in the UC and PRT groups at 12
months compared to baseline (p = 0.02). b Change in SF-36v2 mental component score in the UC and PRT groups at 12 months compared to
baseline (p = 0.01)
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Our study showed an increase in FM in both the UC
and PRT groups but PRT was able to offset a gain in FM
by 3.1 ± 1.0 % (2.3 ± 0.8 kg). This is similar to findings
by Winters-Stone et al. [31] who found a 1.9-kg differ-
ence in FM between the UC and PRT groups after 52
weeks of supervised PRT. Importantly, we found that
PRT had the greatest effect on truncal fat mass. Dicker-
man et al. [32] found that higher visceral fat and waist
circumference, a surrogate of central adiposity, were
associated with advanced and fatal prostate cancer.
Thus, these results provide evidence on the benefits of
home-based PRT programmes in counteracting ADT-
induced negative effects on body composition in the
prostate cancer population.
This study showed significant reductions in muscle
strength and physical function with long-term ADT.
However, there were no significant differences in muscle
strength or physical function between the UC and PRT
groups. Previous studies involving supervised PRT
showed gains in both upper and lower limb strength in
prostate cancer patients [14, 30, 33] and Taafe et al. [14]
reported an improvement in physical function. It is
known that home-based programmes may have lower
adherence, training volume and loading compared to su-
pervised programmes [34], which may have reduced the
potential for strength adaptation or maintenance follow-
ing initiation of ADT in our study.
Our study showed that overall physical activity levels
were higher in the PRT compared to UC group at 12
months. Physical activity is important in prostate cancer
as Phillips et al. found that a higher duration of total,
non-vigorous walking activity in prostate cancer survi-
vors was associated with improved HRQOL [35]. There
is also a correlation between physical activity and re-
duced mortality in prostate cancer patients [36]. Thus,
the finding that a home-based PRT programme can in-
crease physical activity levels are encouraging, given the
insufficient levels of physical activity in the population of
men with prostate cancer, with a study by Silva et al.
showing that 56.5% of a cohort of men with prostate
cancer were inactive [37].
ADT results in a significant decline in bone mass and
an increase in fracture risk [38, 39]. This study demon-
strated a significant decline in BMD at the lumbar spine
as early as 6 months of ADT, which was not attenuated
by PRT. However, other parameters which would influ-
ence bone health, such as vitamin D levels, were not
examined in this study and may have affected results.
Our PRT programme may also have been limited in
terms of the degree of impact loading which is a precipi-
tating factor in upregulating osteoblastic activity to
promote the maintenance or increase in BMD [40]. Only
Winters-Stone et al. [31] has reported preservation of
BMD at the L4 site in patients in the PRT group versus
the control group and thus, the effect of PRT on BMD
during ADT warrants further investigation.
We found an improvement in insulin sensitivity as
measured by the Matsuda Index in the PRT group at 6
weeks, although this difference was not maintained at 6
and 12months. In an RCT involving a supervised PRT
programme in patients on long-term ADT, Winters-
Stone et al. [31] found a non-significant reduction in in-
sulin levels (a surrogate marker of insulin resistance) in
the PRT group compared to an increase in the control
group. In a population of patients with type 2 diabetes, a
home-based PRT programme was also unable to main-
tain the glycaemic benefits obtained from supervised
gymnasium-based PRT [34]. Thus, PRT may have initial
benefits on glucose metabolism that is difficult to sustain
during long-term ADT.
Psychological distress and anxiety is prevalent amongst
men with prostate cancer ranging from 15 to 27%, and
highest in those who have yet to undergo treatment [41].
This was reflected in our findings, which showed a sig-
nificant decline in HRQOL following ADT in the UC
group. We showed that the use of a concurrent home-
based PRT programme at the start of ADT was associ-
ated with significant improvements in HRQOL. This is
in line with the effects of supervised PRT programmes
which showed improvements in fatigue, vitality and
mental health [14, 42]. These results provide evidence
that the mental health benefits of PRT are seen even
when implemented in an unsupervised setting. There are
multiple reasons why exercise can improve mental well-
being. Exercise leads to improved self-esteem [43] and
also induces physiological effects which impact mood
and cognitive function [43]. However, it is important to
note that men in the PRT group had more regular
contact with study co-ordinators. This increases the
participant’s social support network which can im-
prove HRQOL [44].
There are limitations to this study. It is important to
highlight that the sample size in this study was quite
small, and the validity of these findings should be repli-
cated in larger, wide-scale studies. The large number of
outcome measures in relation to the small sample size
raises the possibility of chance findings, although the
positive findings in our study did parallel those found in
previous exercise studies in a similar population. The
small sample size would have affected the ability to
observe differences, particularly in terms of muscle
strength, physical function and the biomarkers assessed.
Men in the PRT group were also relatively well-
functioning individuals with minimal co-morbidities,
who were highly motivated to undertake home-based ex-
ercise. Therefore, this group of participants may not be
representative of men with prostate cancer at large. Men
in the UC group received advice from the treating
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clinician regarding exercise recommendations for men
with prostate cancer [45], but this was non-standardised.
Study outcomes may have differed had a protocolised
approach to exercise recommendations in the UC group
been adopted. Furthermore, participants were asked to
self-record their PRT adherence in a logbook. Although
this is a frequently used adherence method, there is the
possibility of inaccurate reporting with a bias towards
over-reporting [46]. The use of an electronic physical ac-
tivity tracker or smartphone application in future studies
may reduce reporting bias [47].
This study is unique in that it explores the long-term
use of isolated PRT at the start of ADT in a home-based
setting which has not been investigated previously.
Although there is robust data supporting the use of
supervised PRT in prostate cancer patients, it is resource
intensive and may not be feasible to implement across
the whole prostate cancer population. We were able to
demonstrate long-term positive outcomes with a more
cost-effective alternative, estimated to be less than a
third of the total cost of supervised programmes and
hence may be more practical for the translation of exer-
cise rehabilitation as standard practice in cancer care
[17, 18]. The positive outcomes from this study suggest
that guidelines can be modified to maximise exercise
participation in the prostate cancer population. This
involves the early involvement of an exercise physi-
ologist to ensure proper conduct of exercises for
maximal effectiveness and for periodic monitoring of
exercise compliance.
Conclusion
In conclusion, we were able to show that a home-based
PRT programme instituted at the start of ADT was able
to counteract detrimental changes in body composition
and improve both physical activity and mental health over
a 12-month period. This can potentially offer clinicians a
viable alternative to more resource-intensive supervised
programmes when instituted at the commencement of
ADT.
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